当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Shuo Qiu
Currently, there is no consensus on continuing vs. holding buprenorphine preoperatively. Management of post-operative pain in patients on buprenorphine has been hotly debated, with evidence showing for and against stopping buprenorphine prior to surgery. This case series will examine 6 VA patients who have underwent a variety of surgeries with different levels of expected pain. Patients who undergo minor surgeries with low expected pain can safely continue buprenorphine. None of our patients who underwent minor surgeries and continued buprenorphine reported significant pain, even for a patient 5 who underwent cholecystectomy. Patient 2 endorsed additional pain relief when he increased his buprenorphine from 16 to 32 mg daily to help with his post-operative pain.
Patients who underwent major surgeries such as hip replacements and wrist joint arthroplasty held their buprenorphine and transitioned to full mu opioid prescription before restarting buprenorphine. Only one patient had a positive post-operative urine drug screen for opioids. Patients show resiliency against opioid use even when undergoing surgeries involving stopping their buprenorphine. Many approaches exist to manage pain perioperatively in patients prescribed buprenorphine. Regardless of which approach, patients should be monitored perioperatively for craving and withdrawal from opioids.